ALLR: Allarity Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for ALLR
Across the 20 sessions after earlier ALLR headlines, the stock closed higher 12 times and lower 8 times, with a median move of 5.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ALLR | SPY |
|---|---|---|---|
| Oct 30, 2026 | Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue | -2.2% | -1.8% |
| Sep 30, 2026 | Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development | +8.8% | -0.2% |
| Sep 28, 2026 | Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research | -6.0% | -0.7% |
| Sep 15, 2026 | Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development | -5.1% | -0.5% |
| Sep 11, 2026 | Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement | -2.4% | +0.9% |
| Aug 14, 2026 | Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign | +0.7% | -0.2% |
Quantisnow market dataNASDAQ
ALLR
Allarity Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for ALLR
Full ALLR profile on Quantisnow Follow ALLR and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time